The Operator's Edge: PE Taps Manufacturing Vets for Healthcare's Next Wave

NEW YORK, NY – August 24, 2026

On the surface, Avista Healthcare Partners’ announcement that Tom Orr has joined the firm as a Strategic Executive is standard corporate news. A veteran executive with a formidable track record in medical device manufacturing joins a leading private equity firm. But to see it as just another personnel move is to miss the signal for the noise. Orr’s appointment is a potent indicator of a fundamental shift in private equity, where the most valuable asset is no longer just capital, but the deep, granular operational expertise needed to navigate increasingly complex industries.

Avista, a healthcare-focused firm with over $10 billion invested, is placing a clear bet: in the high-stakes, high-regulation world of medical technology, the key to unlocking value lies not just in the boardroom, but on the factory floor. By bringing on Orr, they are acquiring more than a new advisor; they are embedding decades of hard-won manufacturing and operational wisdom directly into their investment engine.

The New Playbook for Private Equity Value

For decades, the private equity model was often caricatured as one of financial engineering—leveraging assets and optimizing balance sheets to generate returns. While financial acumen remains crucial, the primary driver of value has decisively shifted. Industry analysis shows that operational improvements now account for nearly half of all value creation in PE-backed companies, a dramatic increase from less than 20% in the 1980s. The game has changed from buying and selling assets to buying and building businesses.

This evolution has given rise to the 'Strategic Executive' or 'Operating Partner'—seasoned industry leaders integrated into the PE firm to drive this hands-on value creation. They are not merely consultants; they are active participants across the entire investment lifecycle. From validating an investment thesis during due diligence to crafting 100-day post-acquisition plans and mentoring management teams, these executives are the architects of growth. Avista’s model formalizes this, utilizing a dedicated group of Strategic Executives to provide “insight, operational oversight, and senior counsel” to its portfolio.

Rob Girardi, a Partner at Avista, underscored this hands-on philosophy in his comments on Orr's appointment. "Tom is a highly respected leader and trusted partner to management teams, with a hands-on approach to building businesses and deep understanding of complex manufacturing environments," he stated. This highlights the demand for leaders who can do more than strategize—they can execute.

A Specialist for a Specialized Sector

Nowhere is this need for specialized expertise more acute than in medical device contract manufacturing. The sector is booming, with market projections showing a trajectory from roughly $88 billion in 2025 to over $246 billion by 2034. This growth is fueled by an aging population, the rise of chronic disease, and a strategic decision by large Original Equipment Manufacturers (OEMs) to outsource production to focus on R&D and marketing.

However, this is not a simple plug-and-play manufacturing environment. It is a minefield of complexity. Stringent regulatory frameworks from the FDA and international bodies like the EU demand meticulous compliance. Supply chains are global, fragile, and require sophisticated management. Quality control is a matter of life and death, and intellectual property must be fiercely protected. For a private equity firm, navigating these challenges is impossible without genuine, in-the-trenches experience.

This is precisely why a background like Tom Orr’s is in such high demand. His career is a testament to creating value within these complexities. As President and CEO of Seaway Plastics Engineering, he didn't just oversee operations; he transformed the business. He led the firm through a period of significant growth, spearheaded strategic acquisitions like Wright Engineered Plastics and MME Group to expand its medical footprint, and ultimately guided it to a successful sale to a larger private equity group—the quintessential PE success story driven by operational leadership.

From the Factory Floor to the Investment Committee

Orr’s journey from leading manufacturing operations at companies like Pöppelmann Plastics and Seaway to a strategic role at Avista illustrates the career path of the modern industrial expert. His experience in injection molding, complex assembly, and regulated environments provides a granular understanding of what it takes to succeed. This knowledge is critical for evaluating potential investments, identifying operational weaknesses, and implementing effective growth strategies.

His existing role as Chairman of the Board at Bentec Medical, an Avista portfolio company acquired in April 2026, already demonstrates this synergy. Bentec, a specialized manufacturer of complex silicone-based medical components, thrives on its technical expertise and quality. Having an experienced operator like Orr at the helm of the board provides the management team with a strategic partner who speaks their language and understands their challenges.

In his own words, Orr expressed his excitement to formalize this partnership. "Having already had the opportunity to work closely with the Avista team, I have seen firsthand the value they bring to management teams and portfolio companies," he said. "I am excited to join the firm as a Strategic Executive and look forward to helping identify new opportunities and contribute to the continued success of Avista's portfolio."

The Strategy in Action: Avista's Medtech Portfolio

Orr's expertise aligns perfectly with Avista’s established focus on the medtech sector. The firm's portfolio includes not only Bentec but also companies like GCM Holding Corp., an outsourced manufacturer of precision components, and EBI, which specializes in bone growth stimulation devices. Each of these companies operates in a niche requiring deep technical know-how, robust quality systems, and efficient, scalable manufacturing.

For these companies, having access to a resource like Orr is a significant competitive advantage. He can help them navigate supply chain disruptions, optimize production processes, evaluate add-on acquisitions, and ensure they remain on the cutting edge of manufacturing technology. This is the tangible impact of the Strategic Executive model.

In an investment landscape defined by intense competition and high valuations, the ability to generate alpha is increasingly tied to a firm’s ability to make its portfolio companies fundamentally better. Tom Orr's appointment is a clear declaration that for Avista Healthcare Partners, the path to superior returns runs directly through the factory door.